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Sirs: Cerebrotendinous xan-
thomatosis (CTX; MIM#213700) is
an autosomal recessive lipid storage
disorder caused by deficiency of the
enzyme sterol-27-hydroxylase
(CYP27) [1–3]. CYP27 mutations
impair the primary bile acids syn-
thesis, leading to accumulation of
cholesterol and cholestanol in vari-
ous tissues, particularly in the cen-
tral and peripheral nervous sys-
tems, eye lenses, and tendons [2].
The “classical”CTX phenotype in-
cludes the triad of juvenile cataracts,
tendon xanthomas, in particular of
ankle tendons, and progressive ner-
vous system involvement [4–6].
Neurological manifestations in-
clude cognitive decline, psychiatric
disorders, epileptic seizures, pyra-
midal tract dysfunction, cerebellar
signs, and a sensory-motor neu-
ropathy characterized by reduced
numbers of large myelinated axons.
Disease onset varies from early in-
fancy to middle adulthood [6].
Neuroradiological characteristics
include cerebral and cerebellar
white matter hyperintensities, and
distinct signal alterations of the
cerebellar dentate nuclei [7]. CTX
may be successfully treated with
chenodeoxycholic acid [8].
Herein, we report a non-consan-
guineous Swiss CTX family with a
compound heterozygous mutation
in the CYP27 gene, displaying a
striking intra-familial phenotypic
variability. While one patient pre-
sented with “classical” clinical signs
of CTX, her older sister had a
slowly progressive myelopathy as
the only manifestation of the dis-
ease.
At the time of the evaluation, the
index patient (patient 1) was 51
years old. She had a normal child-
hood psychomotor development,
an average school performance,
and a professional training as office
employee. Since early childhood
she had chronic diarrhea without
identifiable cause in spite of re-
peated gastro-intestinal tract inves-
tigations. Aged 25 years, gait dis-
turbance was noted for the first
time. Since the symptoms mani-
fested after a banal viral infection,
a parainfectious meningo-myelitis
was suspected. However, gait dis-
turbance gradually progressed over
the following years. Several cere-
bro-spinal fluid (CSF) examina-
tions were normal. At the age of 35
years, the patient underwent bilat-
eral cataract operation. Aged 45
years, behavioral abnormalities
and cognitive decline became evi-
dent. Four years later, she had a
first episode of severe depression.
Cerebral magnetic resonance imag-
ing (MRI) was reported to be nor-
mal. At the age of 51 years, the pa-
tient was admitted to our
department for further evaluation.
General physical examination
showed no skin lesions, in particu-
lar no tendon xanthomas. Cogni-
tive testing revealed severe impair-
ment of short term memory and
abstract reasoning. Neurological
examination revealed a severely
spastic-ataxic gait, increased mus-
cle tone, mild leg weakness, brisk
tendon reflexes with bilateral ankle
clonus, extensor plantar responses,
and reduced vibration and position
sense of the feet. T2- and FLAIR-
weighted cerebral MRI revealed ar-
eas of increased signal intensity in
the periventricular white matter
and the cerebellum, including the
dentate nuclei (Fig.).
Her one-year-older sister (pa-
tient 2) had also a normal child-
hood psychomotor development, a
good school performance, and un-
derwent a professional training as
secretary. After the age of 25 years,
she developed progressive gait dis-
turbance. Although repeated CSF
analysis including oligoclonal fo-
cusing, and visually evoked poten-
tials were normal, diagnosis of a
primary progressive multiple scle-
rosis was made. At age 28 years,
oral methotrexate treatment was
started but discontinued after a few
years because of adverse effects.
Over the following years, gait dis-
turbance was slowly progressive.
Repeated cerebral MRI’s between
1989 and 1998 were normal, and no
other neurological or systemic
signs or symptoms evolved. In par-
ticular, there were no diarrhea,
cataracts, skin or tendon alter-
ations, impaired cognitive func-
tions, or psychiatric symptoms. At
the age of 52 years, she presented at
our department for further evalua-
tion. There were no cataracts or
tendon xanthomas. Neurological
examination revealed a spastic-
ataxic gait, increased muscle tone,
brisk tendon reflexes, extensor
plantar responses, and slightly im-
paired vibration and position sense
of the feet. Further clinical neuro-
logical testing, including assess-
ment of cognitive functions, was
normal.
The combination of chronic
diarrhea, juvenile-onset cataracts,
cognitive impairment, psychiatric
symptoms, progressive neurologi-
cal signs, and leukoencephalopathy
including the dentate nuclei in the
index patient prompted us to carry
out an evaluation for CTX. Analysis
of serum cholestanol and chole-
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sterol levels, as well as urine bile al-
cohol excretion were performed as
previously described [1]. Both sis-
ters had highly increased serum
cholestanol levels and urine bile al-
cohol excretion, thus confirming
CTX diagnosis (Table). Sequence
analysis of the CYP27 gene was car-
ried out as previously described
[6]. Both sisters were compound
heterozygous for the missense mu-
tations 646G > C (A216P) and
1213C > T (R405W). The daughter
of the index patient, being an ob-
ligate heterozygous mutation car-
rier, had normal biochemical find-
ings (Table). Treatment with
chenodeoxycholic acid was started
in both sisters, and follow-up ex-
aminations are ongoing.
Originally, CTX was defined by
the clinical trial of tendon xan-
thomas, bilateral juvenile-onset
cataracts, and progressive neuro-
logical deterioration [4, 5]. How-
ever, further clinical observations
demonstrated an extended spec-
trum of CTX phenotypes. Tendon
xanthomas were found in only two
thirds of patients with otherwise
“classical” CTX [6, 11]. In contrast,
chronic intractable diarrhea was
not noted initially, but was re-
ported in more than a third of
patients in recent series [11]. In
addition, several patients had a
predominantly spinal CTX pheno-
type [10]. This so-called “spinal
xanthomatosis” was characterized
by a slowly progressive myelopathy
without cerebellar dysfunction,
cognitive decline, or tendon xan-
thomas [10]. As in our patient, in-
dividuals with the spinal CTX
phenotype were prone to be mis-
diagnosed as primary progressive
multiple sclerosis [10].
Both mutations found in our pa-
tients had been previously de-
scribed [6, 9]. The 646G > C muta-
tion results in the replacement of
an alanine residue by a proline at
the last position of exon 3. The mu-
tation leads to very low levels of
CYP27 mRNA, thus confirming its
pathogenicity [9]. Most homozy-
gous 646G > C mutation carriers
develop the severe “classical” CTX
phenotype with early childhood
onset [9]. The 1213C > T mutation
results in the replacement of an
arginine residue by a tryptophane
in exon 7. The mutation exchanges
an evolutionary strongly conserved
amino acid within the coding re-
gion for the adrenodoxin- and
heme-binding sites, which are criti-
cal for the CYP27 enzyme activity.
The 1213C > T mutation has only
been observed in compound
heterozygotes so far [6, 10].
The index patient presented
with several key signs of CTX,
namely juvenile-onset cataracts
and diarrhea. In contrast, her sister
carrying the identical mutations
had a “spinal xanthomatosis” with-
out additional manifestations of
the disease. Although supplemen-
tary CTX-related signs and symp-
toms might still develop in the fu-
ture, the long disease course
represents a strong argument for a
striking intra-familial phenotypic
variability. Noteworthy, twice as
high serum cholestanol levels were
Fig. Cerebral Magnetic Resonance Imaging. Axial T2-weighted images of patient 1 demonstrated supratentorial signal abnormalities predominantly found in the posterior
periventricular white matter (A). Additional infratentorial signal abnormalities were located in the dentate nuclei (arrow; B). The pathological findings are confirmed with
coronar FLAIR images (C)
Table Biochemical Findings
Patient 1 Patient 2 Relative with heterozygous
CYP27 mutation
Cholestanol Serum (µmol/l; N = 3.3–12.5) 139 69 7
Cholesterol Serum (mmol/l; N = 4.7–6.5) 6.4 7.0 4.3
Cholestanol/Cholesterol Ratio (%; N < 0.21) 2.17 0.98 0.16
Bile Alcohols Urine (0 – + + + ; N = 0) +++ +++ 0
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found in the more severely affected
index patient compared with her
sister. Although no conclusions can
be drawn from two patients, and
controlled studies of biochemical
markers and disease severity are
lacking, our findings suggest a cor-
relation between the extent of the
bile acid metabolism impairment
and the clinical phenotype. One
probable explanation for the phe-
notypic variability comprises indi-
vidual differences in additional
metabolic pathways interfering
with tissue accumulation of chole-
sterol and cholestanol, as the capa-
bility of macrophages to eliminate
sterols. Since both patients are
compound heterozygous, preferen-
tial activation of one allele result-
ing in a more severe phenotype
than activation of the other allele
has to be considered as an alterna-
tive explanation for the phenotypic
difference.
In conclusion, our findings con-
firm that CTX may exhibit a strik-
ing intra-familiar phenotypic vari-
ability. In addition, our report
emphasizes the importance of CTX
in the differential diagnosis of mul-
tiple sclerosis. CTX is most proba-
bly an underdiagnosed entity, in
particular in patients with a spinal
CTX phenotype. We propose that
all patients with suspected primary
progressive multiple sclerosis
should be interrogated for chronic
diarrhea. A further biochemical
screening for CTX should be con-
sidered in all patients with a pro-
gressive spinal cord syndrome
without convincing clinical, labora-
tory, or neuroradiological support
for multiple sclerosis, or another
distinct cause of myelopathy. CTX
screening is even mandatory if two
of four clinical criteria are present:
1) juvenile-onset cataracts, 2)
chronic intractable diarrhea, 3)
tendon xanthomas, and 4) progres-
sive neurological symptoms. Al-
though CTX is a rare disorder,
early diagnosis is crucial because
neurological progression may be
slowed or even prevented by an
early appropriate treatment.
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